CLINICAL_TRIALS
trial_result
· 2012-06-06
Clinical Trial Update: Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients [Phase 3]
Summary
A Phase 3 trial evaluating sildenafil for Eisenmenger-associated pulmonary arterial hypertension has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Competence Network for Congenital Heart Defects | Conditions: Pulmonary Arterial Hypertension (PAH) | Phase 3 | Status: TERMINATED